Zentalis Q3: $228.9M Cash Extends Runway to 1H 2028, DENALI Topline Set for 1H 2027
ZNTL sits 44% above its 52-week low of $1.212.
Summary
Zentalis reported Q3 2026 results with $228.9M in cash extending runway into 1H 2028, and set a 1H 2027 DENALI Part 2 topline readout while deferring the FDA accelerated-approval discussion to 2027.
Key Events · Earnings and Guidance · ZNTL
-
Q3 Cash Extends Runway to 1H 2028
Cash, cash equivalents and marketable securities stood at $228.9 million as of September 30, 2026, up from $174.6 million at June 30, 2026 after the August offering, funding operations into 1H 2028.
-
Q3 Net Loss $28.8M
Net loss was $28.8 million ($0.34 per share) versus $26.7 million ($0.37) a year earlier; total operating expenses fell to $31.2 million from $33.7 million.
-
DENALI Topline Set for 1H 2027
Part 2a and 2b enrollment is complete, Part 2c enrollment is scheduled to complete in November 2026, and an integrated topline readout across Parts 2a, 2b and 2c is expected in 1H 2027.
-
FDA Discussion Pushed to 2027
Management plans to discuss the DENALI data with the FDA in 2027 to assess the accelerated approval opportunity, while advancing ASPENOVA to support either an accelerated or full approval pathway.
Analysis · ZNTL · Life Sciences
The quarter itself was unremarkable — a $28.8M net loss and slightly lower operating expenses — but the balance sheet and timeline are what matter. Cash of $228.9M now funds operations into 1H 2028, roughly a year further out than the late-2027 runway previously disclosed, which removes any near-term financing pressure after the August raise. Management also put a date on the DENALI Part 2 integrated topline (1H 2027) and said Part 2c enrollment completes this month, giving investors a concrete readout to trade against. The one caution is regulatory: rather than committing to accelerated approval, Zentalis now says it will discuss the DENALI data with the FDA in 2027 given an evolving PROC landscape, leaving the approval path open to either accelerated or full review.
How filings like this one have moved
In the 30 days to Nov 11, 2026, 36.6% of the 3434 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ZNTL was trading at $1.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $164.7M. The 52-week trading range was $1.21 to $6.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.